Womens Health Therapeutics Market Size - By Drug Type, By Application, By Age Group, By Medication Type, By Distribution Channel, Growth Forecast, 2025 - 2034

Women’s Health Therapeutics Market Size

The global women's health therapeutics market size was valued at USD 44.6 billion in 2024. The market is anticipated to grow from USD 46 billion in 2025 to USD 69.5 billion in 2034, growing at a CAGR of 4.7% from 2025 to 2034, according to the latest report published by Global Market Insights Inc.

The women’s health market is significantly driven by the rising economic and emotional impact of infertility, recognized as a widespread public health issue. According to the World Health Organization (WHO), approximately 17.5% of adults nearly one in six experience infertility at some point in their lives. This condition affects individuals across all income levels, with infertility rates at 17.8% in high-income countries and 16.5% in low- and middle-income nations, highlighting its universal nature.
 

As a result, there is a growing and sustained demand for fertility care services, including diagnostic tools, assisted reproductive technologies (ART), and medications that regulate ovulation and hormonal balance.
 

Women’s health therapeutics market encompasses pharmaceutical and biotechnological treatments addressing female-specific health conditions, including reproductive, hormonal, and menstrual disorders. It focuses on improving women’s wellness through innovative therapies, preventive care, and personalized medicine across various life stages.
 

Beyond policy factors, lifestyle-related risks are intensifying infertility challenges. Increasing obesity rates, delayed childbearing, chronic stress, exposure to environmental toxins, and sedentary habits are contributing to reduced fertility in both sexes. WHO identifies these as key contributors to both primary and secondary infertility. Notably, the trend of women choosing to conceive later in life is linked to declining natural fertility and a growing reliance on reproductive technologies and hormone therapies.
 

The market growth focuses on improving women’s wellness through innovative therapies, preventive care, and personalized medicine across various life stages.
 

Women’s Health Therapeutics Market Trends

• The women’s health therapeutics market is undergoing a transformative shift, driven by rising awareness, technological innovation, and a growing emphasis on preventive care.
   
• Increasing prevalence of chronic conditions such as endometriosis, PCOS, and osteoporosis is fueling demand for targeted therapies. For instance, according to the WHO, the global burden of endometriosis, affecting an estimated 190 million women worldwide, is a key driver for market expansion. Characterized by chronic pelvic pain, infertility, and heavy menstruation, the condition affects up to 15% of reproductive-age women and as much as 70% of those with chronic pelvic pain.
   
• In addition, growing personalized medicine is gaining traction, with treatments tailored to hormonal profiles and genetic markers offering improved efficacy and reduced side effects.
   
• Furthermore, the growing investment in non-hormonal alternatives and biosimilars, responding to consumer demand for safer, long-term solutions.
   
• Public health campaigns and education initiatives are helping break taboos around menstruation and menopause, encouraging early diagnosis and treatment. However, challenges persist, including high treatment costs, regulatory hurdles, and social stigma.
   
• Overall, the market is poised for sustained expansion, with innovation and inclusivity at its core.
   

Women’s Health Therapeutics Market Analysis

Based on the drug type, the women’s health therapeutics market is classified into hormonal therapies, pain and symptom management drugs, GnRH modulators, bone health agents, metabolic drugs fertility drugs and other drug types. The hormonal therapies segment dominates the market was valued at USD 27.5 billion in 2024 and is projected to witness robust growth over the analysis timeframe.
 

• This dominance is driven by the widespread use of hormone replacement therapies (HRT) for managing menopause, osteoporosis, and hormone-sensitive cancers.
   
• Estrogen and progesterone therapies are particularly prevalent due to their effectiveness in alleviating menopausal symptoms and preventing long-term complications.
   
• The segment benefits from strong clinical validation, increasing awareness, and expanding access through both traditional and digital health channels.
   
• On the other hand, pain and symptom management drugs is poised for significant growth in coming years driven by rising awareness of chronic conditions like endometriosis, menopause, and pelvic pain. Increasing demand for non-invasive, personalized treatments and improved access to therapies are driving market expansion across both developed and emerging regions.
   

Based on the application, the women’s health therapeutics market is categorized into contraception, menopause and post-menopausal management, hormonal disorders, endometriosis and uterine fibroids, reproductive health and fertility care, bone health and osteoporosis and other applications. The contraception segment dominated the market with 35.3% market share in 2024.
 

• Rising awareness for family planning, and ongoing advancements in contraceptive methods, increased female workforce participation, and demand for safer, more effective contraceptive options have strengthened contraception demand in the market.
   
• Innovations such as hormonal therapies pills, patches, rings  and non-hormonal vaginal gels for example Phexxi and long-acting reversible contraceptives (LARCs) have expanded choices and improved compliance.
   
• Further, supportive government policies, telehealth platforms, and personalized contraceptive solutions have further boosted accessibility and adoption.
   
• As reproductive health becomes a global priority, the contraception segment continues to anchor market growth and innovation.
   

Based on the medication type, the women’s health therapeutics market is classified into over the counter (OTC) and prescription. In 2024, the prescription segment held the highest market share and is expected to showcase significant growth over the analysis period to reach USD 51.7 billion by 2034.
 

• The dominance stems from their pivotal role in managing multifaceted women health conditions such as menopause, endometriosis, osteoporosis, and other conditions.
   
• Prescription therapeutics are administered under medical supervision providing targeted, regulated, and clinically validated treatment that leads to gaining large customer trust.
   
• Drugs such as Prolia and Orilissa have gained traction due to their effectiveness and government-backed reimbursement policies strengthening the prescription demand.
   
• On the other hand, OTC products are growing in accessibility, especially for contraception and menstrual health, prescription medications remain the backbone of therapeutic interventions due to their precision, efficacy, and regulatory support.
   

Based on the age group, the women’s health therapeutics market is divided into below 20, 21-50, and above 50. The 21-50 segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 4.6%.
 

• The 20-50 age group prominence was driven by the growing demand for reproductive, menstrual, and fertility-related treatments.
   
• This demographic represents the prime reproductive age group with the active phase for a woman towards, family planning, fertility therapies including infertility drugs, prenatal care, contraception and treatments for conditions like PCOS and endometriosis.
   
• For instance, according to World Health Organization (WHO), among the 1.9 billion women of reproductive aging (15-49 years) worldwide in 2021, 1.1 billion have a need for family planning; of these, 874 million are using modern contraceptive methods, and 164 million have an unmet need for contraception. This marked the growing adoption of contraception.
   
• Furthermore, gynecological condition like PCOS, endometriosis, and menstrual disorders are among the most common conditions that get diagnosed and treated between the age of 20 and 40, so this same group will often come across them.
   
• Additionally, lifestyle-related disorders and increased health awareness in this age group have led to higher uptake of preventive screenings and wellness therapies. The segment also benefits from strong digital health engagement, including telemedicine and app-based fertility tracking, further boosting its market share and growth potential.
   
• On the other hand, the age group above 50 remains significant growing fueled by high-prevalence of age-related conditions such as menopause and post-menopausal osteoporosis prompting the need for specialized treatment driving its growth in the market.
   

Based on the distribution channel, the women’s health therapeutics market is categorized into offline channels and online channels. The offline channels segment dominated the market in 2024 and is anticipated to witness growth at a CAGR of 4.6%. The offline channels segment is further classified into hospital pharmacies, retail pharmacies and other offline stores.
 

• The offline channels popularity was asserted to its established presence in hospitals, clinics, and retail pharmacies.
   
• These channels offer direct patient engagement, trusted healthcare provider references, and easier access to prescription and OTC therapeutics making them a preferable option.
   
• This offline distribution remains dominant due to their reliability, regulatory compliance, and integration with traditional healthcare delivery systems, favorable insurance coverage, and routine screening programs, particularly for chronic and reproductive health conditions.
   
• On the other hand, the online channels gain traction and are poised to grow at a significant growth rate fueling by the expanding digital platform, penetration of digital solutions and expanding access to e-commerce and online websites is for in the market.
   

Looking for region specific data?

Download Free PDF

North America Women’s Health Therapeutics Market

North America accounted for 42.5% market share in the women’s health therapeutics industry in 2024 and is anticipated to witness high growth during the forecast timeframe.
 

• North America leads the world in women’s health therapeutics market due to its advanced healthcare infrastructure, extensive public and private spendings, and strong institutional focus on preventive care.
   
• The growing proactive government initiatives through awareness campaign, policy reforms, fundings towards women’s health boost market growth.
   
• For instance, National Heart, Lung, and Blood Institute (NHLBI), sponsored a Women's Health Initiative (WHI), a long-term controlled clinical trial focused on strategies for preventing heart disease, breast and colorectal cancer, and osteoporosis in postmenopausal women. These initiatives mirror wider national dedication to women's health research and integration of preventive screening programs by institutions like NIH and CDC.
   
• In addition, Canada's Minister of Health, invested over USD 1.7 million funding to support projects led by the Society of Obstetricians and Gynecologists of Canada and the Sex Information and Education Council of Canada. Through the Sexual and Reproductive Health Fund, these projects will improve access to vital sexual and reproductive services and reduce barriers to care for these underserved communities, through health care provider training, awareness campaigns, and culturally relevant tools and resources. These supportive initiatives aimed at expanding the market base and encouraging inclusive product development.
   
• Moreover, the growing penetration of digital health, with wide deployment of telemedicine, app-based fertility assistance, and virtual clinics has driven the focus on women health. Thus, the aforementioned factors collectively witnessed North America’s leadership in the global market.
   

The U.S. women’s health therapeutics market was valued at USD 16 billion and USD 16.3 billion in 2021 and 2022, respectively. The market size reached USD 17.1 billion in 2024, growing from USD 16.7 billion in 2023.
 

• The U.S. market growth is driven by rising awareness, increased adoption of preventive care, and expanding access to advanced treatments.
   
• Government initiatives like WHI and funding from NIH and CDC promoted evidence-based therapies and early screening, boosting demand.
   
• Addition, growing adoption of digital health tools, fertility solutions, and health diagnostics solutions also contributes to market growth.
   
• Further, the growing aging population and rising cases of menopause-related conditions further fueled the need for HRT and osteoporosis drugs, sustaining market momentum.
   

Europe Women’s Health Therapeutics Market

Europe women’s health therapeutics industry accounted for USD 13.3 billion in 2024 and is anticipated to show lucrative growth over the forecast period.
 

• Women’s health in Europe benefits from strong public healthcare systems, widespread access to preventive services, and centralized governance across the region
   
• Rising awareness of reproductive and chronic conditions, aging female populations, and structured health disorders screening programs are driving demand for advanced therapeutics.
   
• Further, initiatives under national health frameworks, such as the UK’s NHS and EU-wide health strategies, are increasingly focused on integrating reproductive, mental, and chronic disease care.
   
• Additionally, digital health innovations and collaborations with global pharmaceutical firms are enhancing treatment accessibility and personalization.
   
• With a strong healthcare foundation and growing focus on integrated, patient-centered care, Europe’s women’s health therapeutics market is well-positioned for sustained growth and innovation over the forecast period.
   

Germany dominates the European women’s health therapeutics market, showcasing strong growth potential.
 

• Germany leads the European women’s health therapeutics market due to its robust healthcare infrastructure, proactive government policies, and rising health awareness.
   
• The growth is further driven by increased demand for personalized treatments, preventive care, and early diagnosis.
   
• Germany’s aging female population and growing interest in holistic and digital health solutions further fuel innovation in therapeutics.
   
• Government initiatives, such as the Women’s Health Strategy, and investments in telemedicine and hormonal therapies, position Germany as a dynamic hub for women’s health advancements.
   

Asia Pacific Women’s Health Therapeutics Market

The Asia Pacific women’s health therapeutics industry is expected to witness significant growth over the analysis timeframe.
 

• The Asia Pacific region is widely emerging as a hub for the significant growth driven by rapid urbanization and demographic shifts, including large female population, and increasing life expectancy of driving the demand for specialized care.
   
• Governments across the region are investing heavily in healthcare infrastructure and policy reforms through initiatives.
   
• For example, in May 2025, “Oasis Janani Yatra”, a mobile fertility clinic campaign was initiated by Oasis Fertility in Visakhapatnam, India. The campaign expanded access to fertility and maternal care in underserved areas of Andhra Pradesh and Telangana for 30 days in 30-towns. This initiative delivered education to the communities along with free consultations with fertility specialists, along with complimentary offers for AMH hormone tests, hemoglobin screening, and semen analysis, etc. along with the necessary women’s health care needs. This strategic initiative aimed to expand awareness and educate the communities addressing the concerns of infertility.
   
• Additionally, the growing burden of chronic conditions such as PCOS, osteoporosis, and breast cancer is prompting the need for advanced therapeutics. These factors, combined with rising awareness and regional innovation, are creating a robust foundation for market expansion.
   

China women’s health therapeutics market is estimated to grow with a significant CAGR, in the Asia Pacific women’s health therapeutics market.
 

• The China’s grow is driven by several key factors such as growing aging female population, increasing awareness of reproductive and chronic health issues, and expanding access to healthcare services.
   
• In addition, growing government initiatives aimed at improving maternal and child health, along with rising investments in digital health and personalized medicine, are further accelerating market growth.
   
• The growing prevalence of conditions such as menopausal issues, osteoporosis, hormonal disorders and hormonal disorders is likely prompting the demand for advanced therapeutics.
   
• Furthermore, growing urbanization also contributes to higher healthcare spending and adoption of innovative treatments.
   
• Thus, with strong policy support, demographic momentum, and healthcare modernization, China is emerging as a major growth engine in the Asia Pacific women’s health therapeutics market.
   

Middle East and Africa Women’s Health Therapeutics Market

Saudi Arabia women’s health therapeutics industry is poised to witness substantial growth in Middle East and Africa Women health market during the forecast period.
 

• Saudi Arabia's market is growing rapidly due to a several factors such as growing women population, increased awareness for women health, and the supportive government policies that are likely supporting the women health sector.
   
• For instance, according to the worldbank.org, the total fertility rate in children per woman in Saudi Arabia amounted to 2.28 in 2023. This figure dropped by 5.35 between 1960 and 2023, though the decline. This trajectory decline has driven the major concern expected to drive the demand for women health measures and effective therapeutics in the country.
   
• In addition, the growing supportive government policies further support the market growth. For example, under the Vision 2030 framework, Saudi Arabia has prioritized maternal and child health through increased access to prenatal and postnatal care, mandatory maternal health screenings, and advancements in obstetric emergency response systems. These demographic shifts and policy initiatives are creating strong momentum for growth in Saudi Arabia’s women’s health therapeutics market.
   
• Furthermore, the nationwide deployment of highly trained healthcare professionals, including midwives and obstetricians, has played a critical role in reducing maternal mortality thereby encouraging the growth towards women health in the country.
   
• Besides, women's healthcare digital health programs and collaborations with international healthcare firms will be expected to expand coverage and innovation in treatments, making Saudi Arabia an emerging center for women's healthcare in the Middle East region.
   

Women’s Health Therapeutics Market Share

The women’s health therapeutics industry is shaped by a mix of established global leaders and emerging innovators, creating a dynamic and moderately consolidated competitive landscape. The key players such as Pfizer, Bayer, AbbVie, Amgen and Merck collectively account for a significant portion of the market share estimated to be around 45 - 50%. The companies maintain their dominance in the market through extensive product portfolios including hormonal therapies, fertility drugs, contraceptives, and menopause medications.
 

For example, Bayer leads in hormonal therapies and contraceptives, while AbbVie excels in endometriosis and fibroid treatments. Besides, Amgen’s biologics for bone health and Pfizer’s oncology and hormone therapies reinforce their leadership. They possess enormous distribution platforms globally, obtain regulatory approvals and notable research and development investment which enable them to innovate and lead several segments of therapy.
 

Furthermore, the emerging companies like Organon and Atossa Therapeutics are gaining traction through focused portfolios and acquisitions. The market is shaped by rising awareness, aging populations, and digital health integration. Regional expansion and biosimilar development offer growth opportunities.
 

To strengthen their market positions, leading firms are also adopting multi-pronged strategies including strategic transactions in the form of acquisitions, mergers, and licensing consolidate their leadership position so that they can enter new markets in new geographies and increase therapeutic exposure. This leadership transcends the bottom line and is also seen in their history of presence and credibility in the space of women's health.
 

Women’s Health Therapeutics Market Companies

Few of the prominent players operating in the women’s health therapeutics industry include:

• Allergan (AbbVie)
• Amgen
• Atossa Therapeutics
• Bayer
• Besins
• Cipla
• Evofem 
• Ferring
• Gedeon Richter
• Johnson & Johnson
• Kissei Pharmaceutical
• Lupin
• Novartis
• Organon
• Pfizer
• Sanofi
• Shionogi
• Theramex
   
• AbbVie (Allergan)

AbbVie leads the women health therapeutics market with a share of ~15% in 2024. Its leadership is attributed to its robust portfolio including hormonal therapies and endometriosis treatment with blockbuster drugs such as Orilissa and Lo Loestrin. Its strong research and development pipeline and strategic acquisitions position as a capital in reproductive and menopause care, offering innovative, patient-centric solutions globally.
 

• Amgen

Amgen stands out for its expertise in bone health with Prolia and Evenity, addressing postmenopausal osteoporosis. Its biologics expertise, robust clinical data, and global reach make it a key player in chronic women’s conditions, with a focus on long-term efficacy and safety
 

• Bayer

Bayer is a pioneer in contraception and menopause care, with products like Yaz and Climara. Its integrated portfolio, global footprint, and investment in digital health and sustainability make it a leader in accessible, long-term women’s health solutions
 

Women’s Health Therapeutics Industry News

• In July 2025, Organon acquired MSD’s Biotech production site located in Oss, Netherlands, moving its fertility operations to Organon. This strategic acquisition strengthened Organon’s presence in the Netherlands and ensured a continued global supply of high-quality fertility drugs in the market.
   
• In April 2025, Granta Bio acquired Oviva Therapeutics, a pioneering women's health biotech company focused on advancing treatments that address female physiology, with an emphasis on ovarian aging. This acquisition marked a significant milestone for Granta, expanding its research capabilities in women's health applications.
   
• In February 2025, Adalvo marked a major milestone with the UK launch of Adalvo’s first women’s health product in collaboration with Wyntra. The product aimed to target endometriosis. This initiative enhances access to quality care and expands treatment options for women and healthcare providers.
   
• In July 2024, Evofem Biosciences entered into a strategic agreement with Lupin to acquire its women's health specialty business. This secured Evofem the FDA-approved single-dose antimicrobial agent Solosec for the treatment of sexually transmitted infections (STIs). This acquisition permitted Evofem to expand its offerings in women's health and improve access to innovative and differentiated options for women’s daily lives.
   

The women’s health therapeutics market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 to 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Type

• Hormonal therapies
• Pain and symptom management drugs
• GnRH modulators
• Bone health agents
• Metabolic drugs
• Fertility drugs
• Other drug types

Market, By Application

• Contraception
• Menopause and post-menopausal management
• Hormonal disorders
• Endometriosis and uterine fibroids
• Reproductive health and fertility care
• Bone health and osteoporosis
• Other applications

Market, By Medication Type

• Over the counter (OTC)
• Prescription

Market, By Age Group

• Below 20
• 21-50
• 51 and above

Market, By Distribution Channel

• Offline channels
  • Hospital pharmacies
  • Retail pharmacies
  • Other offline stores
• Online channels

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea

• Latin America
  • Brazil
  • Mexico
  • Argentina

• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE